Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Please read

Nice DD Greeneyes.

So this would explain a lot IMO of why we are where we are. TPL was not ready to risk fighting validity of the patents with the J3 without the PTO stamp of re-approval on them. The licensing effort has stalled due to the PTO review placing doubt on patent validity and the weakness shown in th J3 settlement. TPL realizes the need to get past the re-examination with solid strong patents that will be much harder to be challenged in the future to propell the licensing effort. As Greeneyes DD would suggest, TPL may even be bringing potentially troublesome prior art to the attention of the PTO to deal with it ex-parte now with the PTO rather than in a court room in the future (Gutsy move but it makes a lot of sence). TPL must be very confident in their abilities to convince the PTO that the 148 and 336 patents are different from the prior art identified. I like what TPL is doing. This makes a lot of sence and once re-validated should launch us and propell further licensing. I continue to be impressed by the folks at TPL. They seem to know what they're doing.

Everyone have a safe and happy fourth of July weekend,

Steve

All the best,

Steve

Share
New Message
Please login to post a reply